Sarilumab dans la PPR
LB006. Dasgupta B, Unizony S, Warrington KJ et al. Sarilumab in patients with relapsing polymyalgia rheumatica: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR). Eular 2022. Figure…
Site professionnel spécialisé en Rhumatologie
LB006. Dasgupta B, Unizony S, Warrington KJ et al. Sarilumab in patients with relapsing polymyalgia rheumatica: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR). Eular 2022. Figure…
OP0260. D’Agostino MA, Boers M, Gaillez C et al. Responsiveness of a combined power Doppler and Greyscale ultrasound score for assessing synovitis at joint level in psoriatic arthritis patients with…
OP0268. Montastruc F, Flumian C, Degboe Y et al. Comparison of major cardiovascular and thromboembolic events in safety reports between rheumatoid arthritis patients treated with JAK inhibitors versus anti-TNF: results…
POS0939. Deodhar A, Van der Heijde D, Gensler LS et al. Bimekizumab in patients with active nonradiographic axial spondyloarthritis: 24-week efficacy & safety from BE MOBILE 1, a phase 3,…
OP0249. Machado PM, Schaefer M, Mahil S et al. Characteristics associated with poor Covid-19 outcomes in people with psoriasis and spondyloarthritis: data from the Covid-19 PsoProtect and global rheumatology alliance…
OP0021. Torgutalp M, Rios Rodriguez V, Dilbaryan A et al. Treatment with non-steroidal anti-inflammatory drugs is associated with retardation of radiographic spinal progression in patients with axial spondyloarthritis: 10-year results…
OP0264. Charles-Schoeman C, Szekanecz Z, Giles JT et al. Impact of baseline cardiovascular risk on the incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.…
Chers collègues, chers amis, toutes les bonnes choses ont une fin. Ce congrès de l’Eular 2022 aussi. Je sais que vous avez été assidus au Best of de l’Eular. Merci…
